|Awarded On||August 21, 2019|
|Title||Defining and enabling delivery of microRNA and CRISPR therapeutics for hepatocellular carcinoma (HCC)|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas Southwestern Medical Center|
|Principal Investigator/Program Director||Daniel Siegwart|
|Cancer Sites||Gallbladder, Liver and Intrahepatic Bile Duct|
*Pending contract negotiation
Incident rates of hepatocellular carcinoma (HCC) have more than doubled over the last 20 years in the United States, and no other state has felt the impact more than Texas. The rate for South Texas Hispanic/Latinos is >3 times higher than for US White non-Hispanics. Advanced HCC has an extremely poor prognosis with few therapeutic options. Sorafenib, the only available chemotherapeutic for HCC, extends median survival by only 2.8 months. Recently, 8 Phase III clinical trials with small molecule drugs have failed. These failures highlight the challenge of treating HCC, the need to develop alternative drugs including microRNAs and CRISPR/Cas, and the lack of knowledge regarding cellular spe...